Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial

The Lancet Infectious Diseases

Volumn 12, Issue 4, 2012, Pages 281-289

  Cornely, Oliver A ^a   Crook, Derrick W ^b   Esposito, Roberto ^c   Poirier, André ^d   Somero, Michael S ^e   Weiss, Karl ^f   Sears, Pamela ^g   Gorbach, Sherwood ^g,h  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c Clinica delle Malattie Infettive e Tropicali   (Italy)

^d Centre hospitalier regional de Trois Rivieres   (Canada)

^e University of Montreal ^*  (United States)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g Optimer Pharmaceuticals   (United States)

^h TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; CANADA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEMALE; HUMAN; INTERACTIVE VOICE RESPONSE SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES;

EID: 84859007390     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70374-7     Document Type: Article

References (25)

1. Baxter R, Ray GT, Fireman BH Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008, 29:44-50.
2. Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008, 46(suppl 1):S19-S31.
3. Gerding DN Disease associated with Clostridium difficile infection. Ann Intern Med 1989, 110:255-257.
4. Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377:63-73.
5. Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010, 23:529-549.
6. Miller M, Gravel D, Mulvey M, et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010, 50:194-201.
7. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008, 47:1162-1170.
8. Arvand M, Hauri AM, Zaiss NH, Witte W, Bettge-Weller G Clostridium difficile ribotypes 001, 017, and 027 are associated with lethal C difficile infection in Hesse, Germany. Euro Surveill 2009, 14:19403.
9. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011, 53:440-447.
10. Louie TJ, Emery J, Krulicki W, Byrne B, Mah M OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C difficile infection. Antimicrob Agents Chemother 2009, 53:261-263.
11. Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010, 156:3354-3359.
12. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011, 364:422-431.
13. Bauer MP, Kuijper EJ, van Dissel JT European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009, 15:1067-1079. for the European Society of Clinical Microbiology and Infectious Diseases.
14. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
15. The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD) WHO, (accessed Jan 25, 2012). http://www.who.int/classifications/atcddd/en/.
16. NCI guidelines for investigators: adverse event reporting requirements for DCTD (CTEP AND CIP) and DCP INDs and IDEs National Cancer Institute, (accessed Feb 3, 2012). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf.
17. Shue YK, Sears PS, Shangle S, et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 2008, 52:1391-1395.
18. Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009, 53:223-228.
19. Louie TJ, Emery J, Krulicki W, Byrne B, Mah M OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C difficile infection. Antimicrob Agents Chemother 2009, 53:261-263.
20. Citron DM, Babakhani F, Goldstein EJ, et al. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C difficile infection. Anaerobe 2009, 15:234-236.
21. Aas J, Gessert CE, Bakken JS Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003, 36:580-585.
22. McFarland LV, Elmer GW, Surawicz CM Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002, 97:1769-1775.
23. Golan Y, Louie T, Miller M, et al. Risk of recurrence and time to recurrence following treatment of Clostridium difficile infection: patient characteristics and the differential effect of fidaxomicin vs vancomycin. Digestive Disease Week; Chicago, IL, USA; May 7-10, 2011. 1981.
24. Tenover FC, Akerlund T, Gerding DN, et al. Comparison of strain typing results for Clostridium difficile isolates from North America. J Clin Microbiol 2011, 49:1831-1837.
25. Modena S, Gollamudi S, Friedenberg F Continuation of antibiotics is associated with failure of metronidazole for Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2006, 40:49-54.